サンプル依頼リスト カート
  • English
  • Korean
表紙：がんバイオマーカーの世界市場-2023年～2030年
市場調査レポート
商品コード
1316268

がんバイオマーカーの世界市場-2023年～2030年

Global Cancer Biomarkers Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
がんバイオマーカーの世界市場-2023年～2030年
出版日: 2023年07月27日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

がんバイオマーカーの世界市場は、2022年に132億米ドルに達し、2030年には325億米ドルに達する好成長が見込まれています。世界のがんバイオマーカー市場は、予測期間中（2023～2030年）にCAGR 12.3%で成長すると予測されています。リキッドバイオプシーの出現、ゲノムバイオマーカー、免疫腫瘍学バイオマーカーの使用、人工知能（AI）の統合が、がんバイオマーカー市場の動向の需要を押し上げています。

世界のがんバイオマーカー市場は近年継続的に拡大しています。バイオマーカーは、がんの存在や進行に関する有用な情報を提供できる測定可能な指標です。がんの診断、リスク評価、治療選択、治療反応モニタリングに不可欠です。

世界のがんバイオマーカー市場規模は、バイオマーカーの種類、プロファイリング技術、その他を含む構成要素で構成され、がんバイオマーカー市場シェアの使用率を高めています。がんバイオマーカーの世界市場は、がんの有病率の増加、個別化医療へのシフト、バイオマーカーの技術進歩、早期発見への注目の高まり、標的療法の採用増加などの要因の結果として拡大しています。

市場力学

老年人口の増加ががんバイオマーカー市場の成長を牽引すると予測

老年人口の増加ががんバイオマーカー市場を牽引しています。世界人口の高齢化に伴い、がんは高齢者の間でより一般的になっています。環境中の発がん物質への継続的な曝露、加齢に伴う遺伝子の変化、免疫システムの弱体化などの変数により、高齢者はがんに罹患するリスクが高くなっています。

例えば、世界保健機関（WHO）の2022年報告によると、2030年までに地球上の約6人に1人が60歳以上になるといわれています。この期間内に、60歳以上の世界人口に占める割合は、2020年の10億人から14億人に増加すると予想されています。

研究開発活動の拡大が世界のがんバイオマーカー市場の主要促進要因

研究開発（R&D）活動の活発化により、がんバイオマーカー市場の拡大が見込まれます。研究開発は、新規バイオマーカーの同定、新規診断検査の開発、新規治療ターゲットの探索など、がんバイオマーカーの科学的理解を拡大する上で重要な役割を果たしています。

例えば、2023年4月、フロリダ州立大学の科学者は、数種類のがんに関連する生物学的マーカーを検出する新しい検査を開発しました。Journal of the American Chemical Society誌に発表されたこの研究成果は、金ナノ粒子と標識ペプチドを化学結合で結びつけたセンシング・プラットフォームについて述べています。

金ナノ粒子は、紫外線の存在下で色素が光らないようにします。乳がんに多く含まれるバイオマーカーMMP-14を含む患者サンプルを注入すると、ペプチドの結合が切断されます。その結果、色素を含む粒子が金から分離し、サンプルが発光します。この新たなブレークスルーは、がんバイオマーカーの進歩、市場成長の促進、診断能力の向上に専念する研究開発努力の高まりを浮き彫りにしています。

サンプルの収集と保存における技術的困難が市場成長の妨げになる

サンプルの収集とアクセスは重要な市場制約です。サービスプロバイダーはサンプルを入手する際に課題を抱えており、入手後は強力な品質管理技術が必要となります。サンプルの損失や劣化を防ぐには、適切な保管条件を維持しなければならないです。

さらに、リスク検出、スクリーニング、診断、モニタリングなど、がん管理の明確な段階には異なるサンプルが必要とされます。これらの基準はプロセスに複雑さとロジスティクスの課題を追加し、バイオマーカーに基づく検査と治療の効率的でシームレスな展開を制限する可能性があります。

COVID-19の影響分析

COVID-19の大流行はがんバイオマーカー業界に多大な影響を与えました。がん診断が遅れ、治療研究を含む研究開発業務が中断されました。サプライチェーンの混乱により、バイオマーカー検査機器や材料が不足しました。COVID-19患者の管理に向けたヘルスケアの優先順位のシフトは、バイオマーカーに基づく診断や治療の普及に影響を与えました。

さらに、遠隔医療や遠隔モニタリングが普及したが、対面での評価やバイオマーカー検査には障害となっています。金銭的な制約や市場の不確実性は、バイオマーカーに基づく治療の取り込みや償還に影響を与えました。がん罹患率の変化や新規バイオマーカーの利用可能性など、長期的な影響が市場をさらに複雑にしています。

ロシア・ウクライナ紛争の影響分析

ロシア・ウクライナ紛争は、がんバイオマーカー市場に広範な影響を及ぼす可能性があります。潜在的な影響としては、バイオマーカー関連製品のサプライチェーンの混乱、医療費削減につながる経済の不安定化、研究開発からのリソースの流用、医療インフラへの負担、規制上の問題などが挙げられます。

これらの影響により、バイオマーカー入手の遅延または不足、バイオマーカー技術への投資の減少、バイオマーカー研究の進歩の遅延、ヘルスケアサービスへのアクセスの制限、規制の不確実性の増大が生じる可能性があります。影響の大きさは、紛争の期間と激しさ、および実施される緩和策によって決まる。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • がんの有病率の増加
      • 戦略的開発の増加
    • 抑制要因
      • バイオマーカーの高コスト
    • 機会
      • 個別化医療の発展
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 がん適応症別

  • 肉腫
  • 大腸がん
  • 子宮頸がん
  • 肺がん
  • 乳がん

第8章 バイオマーカータイプ別

  • PSA
  • HER-2
  • EGFR
  • KRAS
  • その他

第9章 プロファイリング技術別

  • オミックス・テクノロジー
  • 細胞遺伝学
  • イムノアッセイ
  • イメージング技術
  • バイオインフォマティクス

第10章 エンドユーザー別

  • 病院
  • 学術機関およびがん研究機関
  • 外来手術センター
  • 診断研究所

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市場ポジショニング/シェア分析
  • M&A分析

第13章 企業プロファイル

  • F. Hoffmann-La Roche Ltd
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Thermo Fisher Scientific, Inc.
  • QIAGEN N.V.
  • Illumina, Inc.
  • Bio-Rad Laboratories, Inc.
  • Abbott Laboratories
  • bioMerieux SA
  • Enzo Biochem, Inc.
  • Merck Millipore
  • Micron Technology

第14章 付録

目次
Product Code: MD578

Market Overview

The global cancer biomarker market reached US$ 13.2 billion in 2022 and is expected to witness lucrative growth by reaching up to US$ 32.5 billion by 2030. The global cancer biomarker market is expected to exhibit a CAGR 12.3% during the forecast period (2023-2030). The emergence of liquid biopsy, use of genomic biomarkers, immuno-oncology biomarkers, and integration of artificial intelligence (AI) are driving up demand for cancer biomarker market trends.

The global cancer biomarker market has been expanding continuously in recent years biomarkers are measurable indicators that can provide useful information regarding the presence or progression of cancer. They are essential in cancer diagnosis, risk assessment, treatment selection, and treatment response monitoring.

The global cancer biomarker market scope comprises components encompassing biomarker types, profiling technologies, and others which has increased usage of cancer biomarker market share. The global market for cancer biomarker is expanding as a result of factors including increasing prevalence of cancer, shift towards personalized medicine, technological advancements in biomarkers, increasing focus on early detection, and rising adoption of targeted therapies.

Market Dynamics

Rising Geriatric Population is Estimated to Drive the Growth of the Cancer Biomarker Market

The growing geriatric population is driving the cancer biomarkers market. Cancer is becoming more common among the elderly as the world population ages. Because of variables such as continuous exposure to carcinogens in the environment, age-related genetic alterations, and a weaker immune system, older persons are at a higher risk of acquiring cancer.

For instance, according to World Health Organization (WHO) 2022 report, by 2030, about one out of every six people on the planet will be 60 or older. Within this time span, the share of the world population aged 60 and up is expected to increase from 1 billion in 2020 to 1.4 billion.

Growing R&D Activities is the Major Driver in the Global Cancer Biomarker Market

The cancer biomarkers market is expected to rise due to increased research and development (R&D) activities. R&D plays an important role in expanding the scientific understanding of cancer biomarkers by identifying novel biomarkers, developing novel diagnostic tests, and exploring new treatment targets.

For instance, on April 2023, Florida State University scientists have developed a novel test for detecting biological markers linked to several types of cancer. Their findings, published in the Journal of the American Chemical Society, describe a sensing platform made up of a gold nanoparticle and labeled peptides linked together by chemical bonds.

The gold nanoparticle keeps the dye from glowing in the presence of UV radiation. When a patient sample carrying the biomarker MMP-14, which is typically present in breast cancer, is injected, the bonds in the peptides are broken. As a result, a dye-containing particle separates from the gold, causing the sample to glow. This new breakthrough highlights the growing R&D efforts devoted to advancing cancer biomarkers, propelling the market growth, and improving diagnostic capabilities.

Technical Difficulties in Collecting and Storing Samples will Hamper the Growth of the Market

Sample collection and access are important market constraints. Service providers have challenges in getting samples, and once obtained, strong quality control techniques are required. To prevent sample loss or degradation, proper storage conditions must be maintained.

Furthermore, different samples are required for distinct stages of cancer management, such as risk detection, screening, diagnosis, and monitoring. These criteria add complexity and logistical challenges to the process, possibly limiting the efficient and seamless deployment of biomarker-based testing and treatments..

COVID-19 Impact Analysis

The COVID-19 pandemic has had a tremendous influence on the cancer biomarkers industry. It delayed cancer diagnoses and interrupted research and development operations, including treatment studies. Supply chain disruptions resulted in a lack of biomarker testing instruments and materials. The shift in healthcare priorities toward managing COVID-19 patients had an impact on the uptake of biomarker-based diagnostics and treatments.

Moreover, telemedicine and remote monitoring gained popularity, but they posed obstacles to in-person assessments and biomarker testing. Financial restrictions and market uncertainty influenced the uptake and reimbursement of biomarker-based treatments. Long-term ramifications, such as changes in cancer incidence and the availability of novel biomarkers, further complicate the market.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict has the potential to have a wide-ranging influence on the cancer biomarker market. Among the potential consequences include disruptions in the supply chain of biomarker-related products, economic instability leading to reduced healthcare spending, diversion of resources away from research and development, strain on healthcare infrastructure, and regulatory issues.

These effects may result in biomarker availability delays or shortages, lower investment in biomarker technology, slowed biomarker research advancement, restricted access to healthcare services, and increased regulatory uncertainties. The magnitude of the impact will be determined by the duration and intensity of the conflict, as well as the mitigation measures implemented.

Segment Analysis

The global cancer biomarker market is segmented based on cancer indication, biomarker type, profiling technology, end user and region.

OMICS Technologies Segment Accounts for 31.1% of Market Share Owing to the Advancement in Technologies in Cancer Research and Collaboration

The cancer biomarkers market is expected to be dominated by the omics technologies segment. The field of cancer research and diagnostics has been completely transformed by omics technologies, which include genomes, proteomics, metabolomics, and transcriptomics. With the use of these technologies, molecular biomarkers may be thoroughly analyzed, revealing important details about the fundamental processes underlying cancer formation, progression, and therapeutic response.

For instance, on June 2023, Owkin committed $50 million to advance cancer research using spatial omics technology in association with NanoString technology and prestigious research institutes. The MOSAIC project, which stands for Multi Omic Spatial Atlas in Cancer, aims to collect the largest spatial omics dataset ever with 7,000 tumor samples. In order to analyze the data and identify immuno-oncology disease subtypes, MOSAIC will use spatial omics approaches, which will aid in the search for biomarkers and medications.

The coalition will promote innovation and advancements in cancer research by utilizing Owkin's AI-based data science technologies as well as NanoString's GeoMx digital spatial profiler and CosMx spatial molecular imager platforms. Thus, owing to the above factors the segment is expected to grow over the forecast period.

Geographical Analysis

North America Accounted for Approximately 40.1% of the Market Share Owing to the Increase in Prevalence of Cancer

North America's market dominance has been facilitated by the higher prevalence of cancer disease, rising aging population, presence of established and influential companies such as technological behemoths, higher collaboration of companies, high purchasing power, and better reimbursement policies.

For instance, according to Centers for Disease Control and Prevention (CDC) statistics of June 2023, There were 1,603,844 newly diagnosed cancer cases in the United States in 2020, and there were 602,347 cancer-related fatalities. This was roughly 144 deaths and 403 new cancer cases for every 100,000 people.

Furthermore, in April 2023, Guardant Health, Inc., a leading precision oncology company, and the Parker Institute for Cancer Immunotherapy (PICI), a network with the world's highest concentration of immuno-oncology (IO) expertise, announced a research collaboration agreement to study the relationship between molecular cancer biomarkers and patient response to immunotherapy treatment across more than 14 different types of cancer. Thus owing to the above factors the region is expected to dominate the market over the forecast period.

Competitive Landscape

The major global players in the cancer biomarker market include: F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, bioMerieux SA, Enzo Biochem, Inc., Merck Millipore, Micron Technology, among others.

Why Purchase the Report?

  • To visualize the global cancer biomarker market segmentation based on cancer indications, biomarker type, profiling technology, end user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of cancer biomarker market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global cancer biomarker market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Cancer Indication
  • 3.2. Snippet by Biomarker Type
  • 3.3. Snippet by Profiling Technology
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Prevalence of Cancer
      • 4.1.1.2. Increase in Strategic Developments
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of Biomarkers
    • 4.1.3. Opportunity
      • 4.1.3.1. Development of Personalized Medicine
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Cancer Indication

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Indication
    • 7.1.2. Market Attractiveness Index, By Cancer Indication
  • 7.2. Sarcoma*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Colorectal Cancer
  • 7.4. Cervical Cancer
  • 7.5. Lung Cancer
  • 7.6. Breast Cancer

8. By Biomarker Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
    • 8.1.2. Market Attractiveness Index, By Biomarker Type
  • 8.2. PSA*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. HER-2
  • 8.4. EGFR
  • 8.5. KRAS
  • 8.6. Others

9. By Profiling Technology

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Profiling Technology
    • 9.1.2. Market Attractiveness Index, By Profiling Technology
  • 9.2. OMICS Technologies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Cytogenetics
  • 9.4. Immunoassays
  • 9.5. Imaging Technologies
  • 9.6. Bioinformatics

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Academic and Cancer Research Institutes
  • 10.4. Ambulatory Surgical Centers
  • 10.5. Diagnostic Laboratories

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Indication
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Profiling Technology
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Indication
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Profiling Technology
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Spain
      • 11.3.7.5. Italy
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Indication
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Profiling Technology
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Indication
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Profiling Technology
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Indication
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Profiling Technology
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. F. Hoffmann-La Roche Ltd*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Thermo Fisher Scientific, Inc.
  • 13.3. QIAGEN N.V.
  • 13.4. Illumina, Inc.
  • 13.5. Bio-Rad Laboratories, Inc.
  • 13.6. Abbott Laboratories
  • 13.7. bioMerieux SA
  • 13.8. Enzo Biochem, Inc.
  • 13.9. Merck Millipore
  • 13.10. Micron Technology

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us